All In Biotech

NDA 022115 · Glaxosmithkline LLC

Lamictal Xr

Lamotrigine · Oral · Anti-epileptic Agent; Mood Stabilizer

Last checked: Nov 20, 2026Latest source record: Oct 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

May 29, 2009

Approved uses

2

Original approval plus efficacy supplements

Registered trials

191

49 Phase 3, 8 recruiting

FAERS reports

132,921

95,830 serious, 11,516 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS SKIN RASHES LAMICTAL XR can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.8% (8 per 1,000) in pediatric patients (aged 2 to 16 years) receiving immediate-release lamotrigine as adjunctive therapy for epilepsy and 0.3% (3 per 1,000) in adults on adjunctive therapy for epilepsy. In a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking adjunctive immediate release lamotrigine, there was 1 rash-related death. LAMICTAL XR is not approved for patients younger than 13 years. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate....

What it is approved for

From the label in effect Oct 10, 2025.

LAMICTAL XR is indicated for: • adjunctive therapy for primary generalized tonic-clonic seizures (PGTC) and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. ( 1.1 ) • conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (AED). ( 1.2 ) Limitation of use: Safety and effectiveness in patients younger than 13 years have not been established. ( 1.3 ) 1.1 Adjunctive Therapy LAMICTAL XR is indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. 1.2 Monotherapy LAMICTAL XR is indicated for conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (AED). Safety and effectiveness of LAMICTAL XR have not been established (1) as initial monotherapy or (2) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.3 Limitation of Use Safety and effectiveness of LAMICTAL XR for use in patients younger than 13 years have not been established.

Mechanism: The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective in preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented seizures in the visually and electrically evoked after-discharge (EEAD) tests for antiepileptic activity. Lamotrigine also displayed inhibitory properties in the kindling model in rats both during kindling development and in the fully kindled state. The relevance of these models to human epilepsy,...

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • LAMICTAL XR · LAMOTRIGINE 300MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • LAMICTAL XR · LAMOTRIGINE 100MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • LAMICTAL XR · LAMOTRIGINE 25MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • LAMICTAL XR · LAMOTRIGINE 250MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • LAMICTAL XR · LAMOTRIGINE 200MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • LAMICTAL XR · LAMOTRIGINE 50MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lamotrigine" as an intervention, any sponsor and status, largest first.

All 191 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective10,467
  • rash8,737
  • seizure6,882
  • nausea6,498
  • off label use6,324
  • fatigue6,299
  • dizziness6,140
  • headache5,868
  • depression5,290
  • vomiting4,887
  • somnolence4,571
  • drug interaction4,529

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,016
20053,052
20063,557
20073,880
20082,377
20094,901
20103,808
20114,992
20125,304
20134,731
20145,234
20157,311
20167,568
20177,268
20188,262
20198,660
20207,763
20217,290
20226,688
20237,031
20247,715
20257,912
20265,600

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lamictal XR (Lamotrigine)

2024 spending

$48.3M

Beneficiaries

1,884

15,467 claims

Per beneficiary

$25,647

$34.14 per unit

View as table
YearSpending
2020$47,581,751
2021$48,413,952
2022$51,122,970
2023$52,699,057
2024$48,318,405

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 896 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.